Wacker Chemie AG has acquired a Dutch site for manufacturing biopharmaceuticals, live microbial products and vaccines, plus the associated business, from SynCo Bio Luxembourg S.\u00e0.r.l.. The Munich-based chemical company announced the acquisition today. For WACKER, maintaining SynCo\u2019s existing customer relationships is a top priority. Moreover, WACKER is keeping on SynCo\u2019s employees. Both parties have agreed not to disclose the purchase price.<\/p>\n
\u201cThis strategic acquisition is a key step for our ongoing expansion in the high-growth biopharmaceuticals market,\u201d explained Auguste Willems of WACKER\u2019s Executive Board. \u201cThe new plant will enable us to satisfy robust market demand today and in the coming years \u2013 and to strengthen our position as a leading contract manufacturer of microbial-derived biopharmaceutical proteins.\u201d<\/p>\n
Founded in 2000, SynCo Bio Partners has some 110 employees and operates two fermentation lines with current capacities of 1,500 and 270 liters. These lines manufacture microbial-derived biopharmaceuticals, not only for clinical testing, but also for the commercial market. There is a further line of single-use fermenters, which provides additional and flexible production capabilities. SynCo\u2019s service offering is rounded out with a \u201cfill and finish\u201d facility, which enables the complete manufacture of pharma\u00adceuticals from the active agent to the filled product. The facilities meet \u201cGood Manufacturing Practice\u201d (GMP) quality standards, and they have already been inspected by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) and approved for the manufacture of specific pharmaceutical proteins.<\/p>\n
\u201cExpanding our production capacity strengthens our market position sustainably,\u201d said Gerhard Schmid, president of WACKER BIOSOLUTIONS. \u201cThe additional fermentation lines double our current capacity, which increases our ability to produce key pharmaceuticals cost effectively, using advanced microbial techniques. We look forward to continuing the comprehensive support for SynCo\u2019s existing customers, while also offering them the proprietary technologies of Wacker Biotech. The acquisition will significantly expand our portfolio of technologies and services.\u201d<\/p>\n
SynCo\u2019s expertise in manufacturing live microbial biopharmaceuticals is a valuable complement to WACKER\u2019s know-how as a full-service supplier. Live microbial products represent a promising new class of actives, offering innovative therapies for serious illnesses and new vaccines against cholera, for example.<\/p>\n